LifeSci Acquisition II in an 8-K filing disclosed that its shareholders voted overwhelmingly in favor of merging with clinical research platform Science 37.
The SPAC did not mention redemptions, if any, although its shares traded at or below the $10 danger zone in the two weeks leading up to the cash-out deadline.
As announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will provide the combined company with approximately $250 million of cash (assuming there were no redemptions from LifeSci’s trust).
Founded in 2014, Science 37 provides a platform for clinical research while optimizing the experience and outcomes for patients and medical scientists. Science 37 offer a range of technology and virtual capabilities, from executing a virtual clinical trial to supplementing a trial as a virtual site, to enabling clinical trials through technology. Read more.
